Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Long-Term Extension in MDD
NCT01395147Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events at 52 weeks, Number of Participants With Markedly Abnormal Laboratory Values and 4 more. Started Jul 2011; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01395147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395147.